Ionizable Lipid Particles for Endosomal Escape and Low Cytotoxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic nucleic acids, such as siRNA and miRNA, face challenges with nuclease digestion in plasma and limited intracellular delivery, leading to stability and efficacy issues, and existing lipid-based carrier systems have not fully addressed these problems.
Innovation Solution
Development of cationic lipid particles that enhance the stability and delivery of nucleic acids by encapsulating them with high efficiency, protecting against degradation and improving intracellular uptake, while maintaining a favorable therapeutic index.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ionizable lipids with pKa between 6-8 are used to reduce cytotoxicity, then cell viability is improved, but transfection efficiency deteriorates due to insufficient endosomal escape capability
Solution Approach 1:
The patent modifies the pKa parameter of ionizable lipids to fall within 6-8, optimizing the balance between cytotoxicity reduction and transfection efficiency. This parameter adjustment allows the lipids to remain sufficiently protonated for endosomal escape while reducing toxic effects on cells.
Solution Approach 2:
The patent creates composite lipid particles combining ionizable lipids with specific structural features (such as cyclic structures and specific chain lengths) to achieve both low cytotoxicity and high transfection efficiency. The composite structure enables synergistic effects where the lipid composition compensates for the limitations of individual components.
2Productivity
If lipid particles are designed for high transfection efficiency, then gene delivery is improved, but cytotoxicity increases causing cell death
Solution Approach 1:
The patent adjusts critical parameters of the lipid molecules including pKa (6-8), chain length (C12-C22), and structural features to reduce cytotoxicity while maintaining transfection efficiency. These parameter optimizations ensure the lipids are sufficiently温和 to cell membranes while retaining ability to facilitate gene delivery.
Solution Approach 2:
The patent introduces specific local structural features in the lipid molecules, such as cyclic structures at specific positions and unsaturation at defined locations, to create localized functional zones that enhance transfection capability without increasing overall cytotoxicity. The local structural modifications allow precise control over lipid behavior.
3Ease of manufacture
If conventional lipid structures are used for simplicity, then manufacturing is easier, but transfection efficiency deteriorates due to lack of optimized molecular features
Solution Approach 1:
The patent defines specific parameter ranges for lipid structures (pKa 6-8, chain lengths C12-C22, specific unsaturation positions) that can be systematically synthesized using established chemical methods. These parameter specifications enable reproducible manufacturing while achieving superior transfection efficiency compared to conventional lipids.
Solution Approach 2:
The patent designs composite lipid structures that combine multiple functional elements (ionizable groups, cyclic structures, specific chain lengths) into unified molecules that can be manufactured through standardized processes. The composite design achieves high transfection efficiency while maintaining manufacturing feasibility through modular molecular architecture.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The cationic lipid particles significantly increase the activity and tolerability of nucleic acids, enhancing their therapeutic index and reducing toxicity, enabling effective intracellular delivery and target protein down-regulation.
Implementation Method 1
the ionizable lipid and the therapeutic cargo it delivers to the cell cytosol
Implementation Method 2
interact with the endosomal membrane in a predictable and controllable manner
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells.